TytoCare is a company that collaborates with leading health plans and providers to introduce Home Smart Clinic solutions, enabling accessible, high-quality primary care from the comfort of home, without compromises. Pulse 2.0 interviewed TytoCare co-founder and CEO Dedi Gilad to gain a better understanding of the company.
Dedi Gilad’s Background
What is Dedi Gilad’s background? Gilad said:
“I come from an engineering background, but my path has always leaned toward creating solutions that blend deep tech with real human impact. Earlier in my career, I worked at multiple technology companies, but it wasn’t until I became a parent and faced repeated, frustrating ER visits with my daughter that I truly understood the gap in how we access care. That experience was a turning point—it pushed me from building technology for its own sake to building technology that could fundamentally change lives.”
Formation Of The Company
How did the idea for the company come together? Gilad shared:
“TytoCare started with a very personal frustration. My daughter suffered from chronic ear infections. We were stuck in a cycle of long drives to the ER, late-night clinic visits, and a whole lot of waiting—all for the same diagnosis and treatment every time. I knew there had to be a smarter way. I envisioned a solution that could bring the capabilities of a clinic into the home and allow a doctor to diagnose remotely with clinical-grade accuracy. That idea grew into TytoCare.”
Favorite Memory
What has been your favorite memory working for the company so far? Gilad reflected:
“There was a moment that really sticks with me—a meet-up with families who had used TytoCare to manage their children’s asthma. One mother told me how her son, who had chronic asthma, hadn’t had to visit the ER in over a year thanks to the device. Instead, they were managing his condition safely from home with support from their doctor. It reminded me why we do what we do. Seeing that kind of impact is incredibly rewarding.”
Core Products
What are the company’s core products and features? Gilad explained:
“Our core product is the TytoCare Home Smart Clinic. It combines a suite of FDA-cleared diagnostic tools with AI-powered guidance and remote clinical workflows. Patients can use TytoCare to perform physical exams—examining heart, lungs, throat, ears, skin. In addition to the home-based solution, we developed the TytoCare Pro Smart Clinic, which replicates the full clinical experience in community centers and rural areas. This allows underserved populations to receive high-quality diagnostic care without needing to travel long distances.”
Challenges Faced
What challenges have Gilad and the team faced in building the company? Gilad acknowledged:
“One of the biggest challenges we’ve faced is driving adoption of virtual care, particularly among populations who have historically been underserved or disengaged from the healthcare system. Medicaid enrollees, for instance, are often less engaged in their healthcare than those who are privately insured. This leads to poorer health outcomes and higher costs. We knew early on that success wouldn’t come just from offering the technology; we had to build engagement and trust.”
“To address this, we created the Tyto Engagement Labs. These labs help us collaborate with health plans and providers to refine strategies for engaging users. We use an evidence-based framework to identify pain points specific to the Medicaid population, such as time savings and access. We then adapt our messaging accordingly: we position it as a convenience and access solution for the whole family. By connecting on the values that matter most to this population, we’ve driven some of our highest engagement rates yet—even with Medicaid users.”
Evolution Of The Company’s Technology
How has the company’s technology evolved since its launch? Gilad noted:
“It’s evolved massively. We started with a core set of exam tools, but over time we’ve layered on real-time AI guidance, automated quality verification, and a full suite of clinical intelligence features. Today, we’re not just capturing data—we’re contextualizing it, verifying it, and helping clinicians make better, faster decisions. We also now have chronic care management which is a testament to how flexible and scalable the platform has become. In 2025, we achieved a significant milestone by completing our AI-powered lung sound suite.”
“With FDA clearance for Tyto Intelligence for Wheeze, Crackle and Rhonchi Detection, TytoCare became the first company globally to offer AI-based detection of all three major abnormal lung sounds. This advancement enhances our Home Smart Clinic solution, enabling providers to deliver faster, more accurate diagnoses for respiratory conditions directly from patients’ homes.”
Significant Milestones
What have been some of the company’s most significant milestones? Gilad cited:
“Getting FDA clearance was a critical milestone—it opened doors in the U.S. market and validated the clinical quality of our solution. Another major moment was during the COVID-19 pandemic, when demand surged and we partnered with some of the largest health systems and insurers in the U.S. We were also selected by leading global providers like the NHS and Clalit. And of course, reaching over 1.5 million users across multiple continents was a powerful indicator of our global impact.”
Customer Success Stories
When asking Gilad about customer success stories, he highlighted:
“Absolutely. One that stands out is a large health plan that deployed TytoCare across a rural population with limited access to clinics. Over 12 months, they reduced ER visits by 30% and increased primary care engagement by over 50%. In another case, school nurses used TytoCare to connect students with remote pediatricians, helping children get care faster while avoiding parent work disruptions. For instance, Cone Health’s school-based virtual care program reported that 95% of students returned to the classroom the same day after receiving care, and there was a 30% reduction in chronic absenteeism. These are real, measurable impacts on access, cost, and outcomes.”
Funding/Revenue
When asking Gilad about the company’s funding and revenue details, he revealed:
“We’ve raised over $200 million to date from top-tier investors. We’re not sharing revenue specifics, but I can say we’ve seen consistent double-digit growth, with strong unit economics and recurring revenue across enterprise and provider contracts.”
Total Addressable Market
What total addressable market (TAM) size is the company pursuing? Gilad assessed:
“We’re targeting the global virtual care market, which is projected to exceed $250 billion by the end of the decade. But more specifically, we see a massive opportunity in transforming primary care and chronic care at home, which accounts for the bulk of healthcare touchpoints. In the U.S. alone, over 400 million primary care visits happen annually, and a large percentage of those can be handled via TytoCare.”
Differentiation From The Competition
What differentiates the company from its competition? Gilad affirmed:
“We’re not another telehealth app. TytoCare serves the entire family, including adults, children, and seniors, across multiple care modalities, including urgent care, virtual primary care, chronic condition management, and longitudinal care programs, all from the comfort of home. On top of that, we’re the only company with a combination of FDA clearance, real-world data at scale, and AI-driven quality verification that makes remote diagnosis truly reliable.”
Future Company Goals
What are some of the company’s future goals? Gilad emphasized:
“AI is transforming every aspect of our lives, and it will transform primary care as we know it as well. I can’t share all of the details yet, but we are working on using our dataset, which is the world’s largest multi-modal health dataset, to tackle the primary care crisis. Primary care is in crisis, marked by clinician shortages, surging demand, and fractured access to consistent care. Today, 30% of Americans lack access to a primary care physician, and the U.S. is projected to face a shortfall of up to 40,000 PCPs by 2036. We are going to use our unmatched dataset—including 1.8 million lung sound recordings, 1.3 million temperature records, 1.2 million ear images, 800,000 heart sounds, 600,000 throat images, and 300,000 skin to change virtual healthcare as we know and consume it today.”
Additional Thoughts
Any other topics you would like to discuss? Gilad concluded:
“Just this: we often think of healthcare transformation in abstract terms—systems, policies, infrastructure. But for me, it always comes back to the individual. A kid who doesn’t have to miss school. A parent who can avoid a 3am ER visit. A rural patient who finally gets consistent care. That’s the kind of future we’re building toward at TytoCare, and it’s what keeps me and the team motivated every day.”
